Neurol. praxi. 2017;18(6):394-398 | DOI: 10.36290/neu.2018.055

Kognice and multiple sclerosis

MUDr. Eva Hynčicová, MUDr. Eva Meluzínová, doc. MUDr. Jan Laczó, Ph.D.
Neurologická klinika 2. LF UK a FN Motol, Praha

Multiple sclerosis (MS) is a chronic disease of the central nervous system leading primarily to motor and sensitive disability. Cognitivedeficit is present in almost 70 % of patients with MS and is detectable even at the earliest stage of MS – in patients with clinicallyisolated syndrome (CIS). Because cognitive deficit has an important impact on a patients‘ quality of life, it is important to focus ontheir potential cognitive deficit in routine clinical practice. The aim of this review is to summarize new findings about cognitivedeficit and neuropsychiatric symptoms in patients with MS and to describe how to manage cognitive deficit in patients with MS.

Keywords: multiple sclerosis, cognitive deficit, neuropsychological tests, Brief Internatiol Cognitive Assessment for Multiple
Sclerosis, Minimal Assessment of Cognitive Function in Multiple Sclerosis, quality of life

Received: September 3, 2018; Accepted: September 4, 2018; Published: December 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hynčicová E, Meluzínová E, Laczó J. Kognice and multiple sclerosis. Neurol. praxi. 2017;18(6):394-398. doi: 10.36290/neu.2018.055.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Amato MP, Langdon D, Montalban X, Benedict RH, DeLuca J, Krupp LB, Thompson AJ, Comi G. Treatment of cognitive impairment in multiple sclerosis: position paper. J Neurol. 2013; 260(6): 1452-1468. Go to original source... Go to PubMed...
    2. Amato MP, Zipoli V, Portaccio E. Cognitive changes in multiple sclerosis. Expert Rev Neurother. 2008; 8(10): 1585-1596. Go to original source... Go to PubMed...
    3. Benedict RH, Cookfair D, Gavett R, Gunther M, Munschauer F, Garg N, Weinstock-Guttman B. Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc. 2006; 12(4): 549-558. Go to original source... Go to PubMed...
    4. Calabrese M, Agosta F, Rinaldi F, Mattisi I, Grossi P, Favaretto A, Atzori M, Bernardi V, Barachino L, Rinaldi L, Perini P, Gallo P, Filippi M. Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. Arch Neurol 2009; 66(9): 1144-1150. Go to original source... Go to PubMed...
    5. Diamond BJ, Johnson SK, Kaufman M, Graves L. Relationships between information processing, depression, fatigue and cognition in multiple sclerosis. Arch Clin Neuropsychol. 2008; 23: 189-199. Go to original source... Go to PubMed...
    6. Dusankova JB, Kalincik T, Havrdova E, Benedict RH. Cross cultural validation of the Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS) and the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). Clin Neuropsychol. 2012; 26(7): 1186-1200. Go to original source... Go to PubMed...
    7. Feinstein A, Feinstein KJ, Gray T, O'Connor P. The prevalence and neurobehavioral correlates of pathological laughing and crying in multiple sclerosis. Arch Neurol 1997; 54: 1116-1121. Go to original source... Go to PubMed...
    8. Feuillet L, Reuter F, Audoin B, Malikova I, Barrau K, Cherif AA, Pelletier J. Early cognitive impairment in patients with clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler. 2007; 13(1): 124-127. Go to original source... Go to PubMed...
    9. Havrdová E a kolektiv. Roztroušená skleróza. Praha 2013: 117-142.
    10. Chiaravalloti ND, DeLuca J. Cognitive impairment in multiple sclerosis. Lancet Neurol. 2008; 7(12): 1139-1151. Go to original source... Go to PubMed...
    11. Johnson SK, Diamond BJ, Rausch S, Kaufman M, Shiflett SC, Graves L. The effect of Ginkgo biloba on functional measures in multiple sclerosis: a pilot randomized controlled trial. Explore (NY). 2006; 2(1): 19-24. Go to original source... Go to PubMed...
    12. Kappos L, Radue EW, Chin P, Ritter S, Tomic D, Lublin F. Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis. J Neurol. 2016; 263(2): 354-60. Go to original source... Go to PubMed...
    13. Lazeron RH, Boringa JB, Schouten M, Uitdehaag BM, Bergers E, Lindeboom J, Eikelenboom MI, Scheltens PH, Barkhof F, Polman CH. Brain atrophy and lesion load as explaining parameters for cognitive impairment in multiple sclerosis. Mult Scler 2005; 11(5): 524-531. Go to original source... Go to PubMed...
    14. Minden SL, Schiffer RB. Affective disorders in multiple sclerosis: Review and recommendations for clinical research. Arch Neurol 1990; 47: 98-104. Go to original source... Go to PubMed...
    15. Nocentini U, Bozzali M, Spano B, Cercignani M, Serra L, Basile B, Mannu R, Caltagirone C, De Luca J. Exploration of the relationships between regional grey matter atrophy and cognition in multiple sclerosis. Brain Imaging Behav 2014; 8(3): 378-386. Go to original source... Go to PubMed...
    16. O'Carroll CB, Woodruff BK, Locke DE, Hoffman-Snyder CR, Wellik KE, Thaera GM, Demaerschalk BM, Wingerchuk DM. Is donepezil effective for multiple sclerosis-related cognitive dysfunction? A critically appraised topic. Neurologist. 2012; 18(1): 51-54. Go to original source... Go to PubMed...
    17. Parmenter BA, Weinstock-Guttman B, Garg N, Munschauer F, Benedict RH. Screening for cognitive impairment in multiple sclerosis using the Symbol digit Modalities. Test. Mult Scler. 2007; 13(1): 52-57. Go to original source... Go to PubMed...
    18. Patten SB, Svenson LW, Metz LM. Psychotic disorders in MS: Population-based evidence of an association. Neurology 2005; 65: 1123-1125. Go to original source... Go to PubMed...
    19. Penner IK, Kappos L, Rausch M, Opwis K, Radü EW. Therapy-induced plasticity of cognitive functions in MS patients: insights from fMRI. J Physiol Paris. 2006; 99(4-6): 455-462. Go to original source... Go to PubMed...
    20. Peyro Saint Paul L, Creveuil C, Heinzlef O, De Seze J, Vermersch P, Castelnovo G, Cabre P, Debouverie M, Brochet B, Dupuy B, Lebiez P, Sartori É, Clavelou P, Brassat D, Lebrun-Frenay C, Daplaud D, Pelletier J, Coman I, Hautecoeur P, Tourbah A, Defer G. Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study. J Neurol Sci. 2016; 363: 69-76. Go to original source... Go to PubMed...
    21. Preziosa P, Rocca MA, Pagani E, Stromillo ML, Enzinger C, Gallo A, Hulst HE, Atzori M, Pareto D, Riccitelli GC, Copetti M, De Stefano N, Fazekas F, Bisecco A, Barkhof F, Yousry TA, Arévalo MJ, Filippi M; MAGNIMS Study Group. Structural MRI correlates of cognitive impairment in patients with multiple sclerosis: A multicenter study. Hum Brain Mapp. 2016; 37(4): 1627-1644. Go to original source... Go to PubMed...
    22. Rabins PV. Euphoria in multiple sclerosis. In: Rao SM (ed) Neurobehavioral aspects of multiple sclerosis. Oxford University Press, New York, 1990: 180-185.
    23. Rao SM, Grafman J, DiGiulio D, Mittenberg W, Bernardin L, Leo GJ, Luchetta T, Unverzagt F. Memory dysfunction in multiple sclerosis: its relation to working memory, semantic encoding and implicit learning. Neuropsychology 1993; 7: 364-374. Go to original source...
    24. Sadovnick AD, Eisen K, Ebers GC, Paty DW. Cause of death in patients attending multiple sclerosis clinics. Neurology 1991; 41: 1193-1196. Go to original source... Go to PubMed...
    25. Sandroff BM, Schwartz CE, DeLuca J. Measurement and maintenance of reserve in multiple sclerosis. J Neurol. 2016; 263(11): 2158-2169. Go to original source... Go to PubMed...
    26. Smith SJ, Young CA. The role of affect on the perception of disability in multiple sclerosis. Clin Rehabil 2000; 14: 50-54. Go to original source... Go to PubMed...
    27. Tekok-Kilic A, Benedict RH, Weinstock-Guttman B, Dwyer MG, Carone D, Srinivasaraghavan B, Yella V, Abdelrahman N, Munschauer F, Bakshi R, Zivadinov R. Independent contributions of cortical gray matter atrophy and ventricle enlargement for predicting neuropsychological impairment in multiple sclerosis. NeuroImage 2007; 36(4): 1294-1300. Go to original source... Go to PubMed...
    28. Téllez N, Río J, Tintoré M, Nos C, Galán I, Montalban X. Fatigue in multiple sclerosis persists over time: a longitudinal study. J Neurol. 2006; 253(11): 1466-1470. Go to original source... Go to PubMed...
    29. Vachová M. Epidemie roztroušené sklerózy ve světě? Cesk Slov Neurol N 2012; 75/108(6): 701-706.
    30. Vleugels L, Lafosse C, van Nunen, Nachtergaele S, Ketelaer P, Charlier M, Vandenbussche E. Visuospatial impairment in multiple sclerosis patients diagnosed with with neuropsychological tasks. Mult Scler, 2000; 6: 241-254. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.